Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Real World Experience with a Zuma -1 Cohort 4 Adopted Approach to CRS and Icans in CAR-T Recipients

Chiranjeevi Sainatham, Olga Goloubeva, Philip Margiotta, Hanan Alharthy, Imari Patel, Ali Bukhari, Jennie Law, Seung Tae Lee, Mehmet H. Kocoglu, Jean A. Yared, Nancy M. Hardy, Maggie Nelson, Joseph P McGuirk, Aaron P. Rapoport, Saurabh Dahiya, Forat Lutfi

Blood (2023) 142 (Supplement 1): 2122.

https://doi.org/10.1182/blood-2023-183002

Published: 2023

Journal Articles

In Vivo Anti-BCMA CAR T-Cell Expansion Kinetics Correlate with Early IMWG Response in RRMM: A Single Institution Study with Comparative Analysis of Idecabtagene Vicleucel and Ciltacabtagene Autoleucel

Mehmet H. Kocoglu, Aaron P. Rapoport, Tim Luetkens, Etse Gebru, Destiny Omili, Jean A. Yared, Nancy M. Hardy, Soren M Bentzen, Ashraf Z. Badros, Djordje Atanackovic

Blood (2023) 142 (Supplement 1): 1973.

https://doi.org/10.1182/blood-2023-189468

Published: 2023

Journal Articles

Clinical Outcomes of CD19 CAR-T-Cell Therapy with Axi-Cel in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) with and without Prior Autologous Stem Cell Transplant

David Tong Chen, Olga Goloubeva, Hanan Alkhaldi, Aaron P. Rapoport, Saurabh Dahiya, Nancy M. Hardy, Djordje Atanackovic, Mehmet Hakan Kocoglu, Forat Lutfi, Jean A. Yared

Blood (2022) 140 (Supplement 1): 9526–9527.

https://doi.org/10.1182/blood-2022-158281

Published: 2022

Journal Articles

Vaccine-induced T-cell responses against SARS-CoV-2 and its Omicron variant in patients with B cell–depleted lymphoma after CART therapy

Blood (2022) 140 (2): 152–156.

https://doi.org/10.1182/blood.2022016175

Published: 2022

Includes: Supplemental data

Journal Articles

Hematopoietic Cell Transplantation of Higher CD34+ Cell Doses and Specific CD34+ Subsets Mobilized with Motixafortide and/or G-CSF Is Associated with Rapid Engraftment - a Post-Hoc Analysis of the Genesis Trial

Blood (2021) 138 (Supplement 1): 2849.

https://doi.org/10.1182/blood-2021-146783

Published: 2021

Journal Articles

Eight-Day Point of Care CAR T-Cell Manufacturing on Clinimacs Prodigy from Healthy Donors As a Proof-of-Concept Study

Kim G. Hankey, Tim Luetkens, Stephanie Avila, John McLenithan, John Braxton, Karen Underwood, Clarissa Saba, Rena G. Lapidus, Forat Lufti, Philip Margiotta, Jean A. Yared, Nancy M. Hardy, Ulrike Abramowski-Mock, Joerg Mittelstaet, Ron Dudek, Xiaoxuan Fan, Djordje Atanackovic, Aaron P. Rapoport, Saurabh Dahiya

Blood (2021) 138 (Supplement 1): 2851.

https://doi.org/10.1182/blood-2021-154013

Published: 2021

Journal Articles

Impaired mRNA Based COVID-19 Vaccine Response in Patients with B-Cell Malignancies after CD19 Directed CAR-T Cell Therapy

Saurabh Dahiya, Tim Luetkens, Stephanie Avila, Saurabh Dahiya, Philip Margiotta, Kim Hankey, Patricia Lesho, Sherri Bauman, Nancy Smith, Kathleen Ruehle, Seung-Tae Lee, Jennie Y. Law, John Baddley, Mehmet Hakan Kocoglu, Jean A. Yared, Nancy M. Hardy, Aaron P. Rapoport, Djordje Atanackovic

Blood (2021) 138 (Supplement 1): 1738.

https://doi.org/10.1182/blood-2021-153949

Published: 2021

Journal Articles

Imaging Biomarkers to Predict Outcomes in Patients with Large B-Cell Lymphoma with a Day 28 Partial Response By PET/CT Imaging Following CAR-T Therapy

Blood (2021) 138 (Supplement 1): 3876.

https://doi.org/10.1182/blood-2021-154225

Published: 2021

Journal Articles

Motixafortide (BL-8040) and G-CSF Versus Placebo and G-CSF to Mobilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: The Genesis Trial

Blood (2021) 138 (Supplement 1): 475.

https://doi.org/10.1182/blood-2021-144296

Published: 2021

Journal Articles

Low Utility of the H-Score and HLH-2004 Criteria to Identify Patients with Secondary Hemophagocytic Lymphohistiocytosis after CAR-T Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Dong Won Kim, MD, Forat Lutfi, MD, Facundo Zafforoni, BS, Moaath Mustafa Ali, MD MPH, Ali Bukhari, MD, David Gottlieb, MD, Seung-Tae Lee, MD PhD, Mehmet Hakan Kocoglu, MD, Nancy M. Hardy, MD, Jean A. Yared, MD, Aaron P. Rapoport, MD, Jennie Y. Law, MD, Saurabh Dahiya, MD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-141992

Published: 2020

Journal Articles

The Impact of Bridging Therapy Prior to CAR-T Cell Therapy on Clinical Outcomes of Patients with Relapsed Refractory Large B-Cell Lymphoma

Forat Lutfi, MD, Ankit Kansagra, MD, Moaath Mustafa Ali, MD, Ali Bukhari, MD, Jonathan Siglin, BS, Jingsheng Yan, PhD, Santanu Samanta, MD, Noa G. Holtzman, MD, David Gottlieb, MD, Dong Won Kim, MD, Seung-Tae Lee, MD PhD, Mehmet Hakan Kocoglu, MD, Jean A. Yared, MD, Nancy M. Hardy, MD, Jason Molitoris, MD, Pranshu Mohindra, MD, Aaron P. Rapoport, MD, Saurabh Dahiya, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-141231

Published: 2020

Journal Articles

Long-Term Outcomes of Busulfan, Fludarabine and 400 Cgy Total Body Irradiation Versus Busulfan and Fludarabine Reduced-Intensity Conditioning Regimens for Allogeneic Stem Cell Transplantation in Hematologic Diseases: A Large Single Center Experience

Justin N. Malinou, MD, Hanan Alkhaldi, MD, Saurabh Dahiya, MD, Olga Goloubeva, PhD MSc, Ali Bukhari, MD, Forat Lutfi, MD, Gabriela Sanchez-Petitto, MD, Santanu Samanta, MD, Aaron P. Rapoport, MD, Nancy M. Hardy, MD, Nicolette Minas, MS, Kathleen Ruehle, RN, Natalie Gahres, RN, Linda Ridge, RN, BA, CCTC, Pranshu Mohindra, MD, Jason Molitoris, MD, Jean A. Yared, MD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-142140

Published: 2020

Journal Articles

A Single-Arm, Open-Label Phase 1 Study of Itacitinib (ITA) with Calcineurin Inhibitor (CNI)-Based Interventions for Prophylaxis of Graft-Versus-Host Disease (GVHD; GRAVITAS-119)

Hannah Choe, MD, Nirav N. Shah, MD, Patrice Chevallier, MD PhD, Marie Thérèse Rubio, MD PhD, Mark A. Schroeder, MD, Nancy M. Hardy, MD, Patrick J. Stiff, MD, Carlos Solano, MD PhD, Ibrahim Yakoub-Agha, Jonathan A. Gutman, MD, Scott D. Rowley, MD, Maria Caterina Mico', MD, Elisabetta Terruzzi, MD, Rafael F. Duarte, MD PhD FRCP, Rodica Morariu-Zamfir, MD, Michael Arbushites, Kai Ding, PhD, Miguel-Angel Perales, MD

Blood (2020) 136 (Supplement 1): 50–51.

https://doi.org/10.1182/blood-2020-140747

Published: 2020

Journal Articles

Bridging the Gap in Access to Transplant for Underserved Minority Patients Using Mismatched Unrelated Donors and Post-Transplant Cyclophosphamide: A National Marrow Donor Program/be the Match (NMDP/BTM) Initiative

Blood (2020) 136 (Supplement 1): 48–49.

https://doi.org/10.1182/blood-2020-137677

Published: 2020

Journal Articles

Increased Cortical Glycolysis Following CD19 CART Therapy: A Radiographic Surrogate for an Altered Blood-Brain Barrier

Ali Bukhari, MD, Vivek Kesari, MD, Reza Sirous, MD, Noa G. Holtzman, MD, Seung Tae Lee, MD PhD, Natalie Gahres, RN, Elizabeth Hutnick, RN, Kathleen Ruehle, RN, Mehmet Hakan Kocoglu, MD, Ashraf Z. Badros, Jean A. Yared, MD, Nancy M. Hardy, MD, Aaron P. Rapoport, Babak Saboury, MD MPH, Saurabh Dahiya, MD

Blood (2019) 134 (Supplement_1): 4454.

https://doi.org/10.1182/blood-2019-125794

Published: 2019

Journal Articles

Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CAR-T) for Large B-Cell Lymphoma: Predictive Biomarkers and Clinical Outcomes

Noa G. Holtzman, MD, Soren M. Bentzen, PhD DMSc, Vivek Kesari, MD, Ali Bukhari, MD, Firas El Chaer, MD, Elizabeth Hutnick, RN, Kathleen Ruehle, RN, Natalie Gahres, RN, Neil Porter, MD, Carl Shanholtz, MD, Mehmet Hakan Kocoglu, MD, Ashraf Z. Badros, Babak Saboury, MD MPH, Jean A. Yared, MD, Nancy M. Hardy, MD, Aaron P. Rapoport, Saurabh Dahiya, MD

Blood (2019) 134 (Supplement_1): 3239.

https://doi.org/10.1182/blood-2019-125400

Published: 2019

Journal Articles

Sublingual Microcirculatory Imaging As a Novel Tool to Monitor for Cytokine Release Syndrome after Chimeric Antigen Receptor T-Cell Therapy

Andrew Deitchman, MD, Michael McCurdy, MD, Muhammad Gilani, MBBS, Aaron P. Rapoport, MD, Kathleen Ruehle, RN, Nancy M. Hardy, MD, Elizabeth Hutnick, RN, Jean Yared, MD, Saurabh Dahiya, MD

Blood (2018) 132 (Supplement 1): 5408.

https://doi.org/10.1182/blood-2018-99-115393

Published: 2018

Journal Articles

Similar Survival for African American and Caucasian Multiple Myeloma Patients Receiving Auto-SCT

Cameron Dell, BS, Olga Goloubeva, PhD MSc, Aaron P. Rapoport, MD, Mehmet H. Kocoglu, MD, Nancy M. Hardy, MD, Jean Yared, MD, Ning Ma, CRNP, Ashraf Z. Badros, MD

Blood (2017) 130 (Supplement 1): 2177.

https://doi.org/10.1182/blood.V130.Suppl_1.2177.2177

Published: 2017

Journal Articles

Plasma Cell Leukemia (PCL): Clinical Characteristics, Outcomes, and the Impact of Circulating Plasma Cells (CPC) Percentage — A Single Center Experience

Noa G. Holtzman, MD, Olga Goloubeva, PhD MSc, Zeba Singh, MBBS, Sameer Sawhney, MD, Ying Zou, MD PhD, Jean Yared, MD, Nancy M. Hardy, MD, Aaron P. Rapoport, MD, Mehmet H. Kocoglu, MD, Ashraf Z. Badros, MD

Blood (2017) 130 (Supplement 1): 3035.

https://doi.org/10.1182/blood.V130.Suppl_1.3035.3035

Published: 2017

Journal Articles

Immunohematology and Transfusion Support of a Patient with Acute Myeloid Leukemia and an Anti-Vel

Jennifer J. O'Brien, MD PhD, Najeebah A. Bade, MD BS, BA, Agnes Hallie Lee-Stroka, Sakhone B. Learn, Sandra Nance, Christine A. Tremblay, Heather L. McGann, Patricia A. R. Brunker, MD DPhil, Nancy M. Hardy, MD, Maria R. Baer, MD, Magali J. Fontaine, MD PhD

Blood (2017) 130 (Supplement 1): 4932.

https://doi.org/10.1182/blood.V130.Suppl_1.4932.4932

Published: 2017

NARROW

Real World Experience with a Zuma -1 Cohort 4 Adopted Approach to CRS and Icans in CAR-T Recipients

In Vivo Anti-BCMA CAR T-Cell Expansion Kinetics Correlate with Early IMWG Response in RRMM: A Single Institution Study with Comparative Analysis of Idecabtagene Vicleucel and Ciltacabtagene Autoleucel

Clinical Outcomes of CD19 CAR-T-Cell Therapy with Axi-Cel in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) with and without Prior Autologous Stem Cell Transplant

Vaccine-induced T-cell responses against SARS-CoV-2 and its Omicron variant in patients with B cell–depleted lymphoma after CART therapy

Hematopoietic Cell Transplantation of Higher CD34+ Cell Doses and Specific CD34+ Subsets Mobilized with Motixafortide and/or G-CSF Is Associated with Rapid Engraftment - a Post-Hoc Analysis of the Genesis Trial

Eight-Day Point of Care CAR T-Cell Manufacturing on Clinimacs Prodigy from Healthy Donors As a Proof-of-Concept Study

Impaired mRNA Based COVID-19 Vaccine Response in Patients with B-Cell Malignancies after CD19 Directed CAR-T Cell Therapy

Imaging Biomarkers to Predict Outcomes in Patients with Large B-Cell Lymphoma with a Day 28 Partial Response By PET/CT Imaging Following CAR-T Therapy

Motixafortide (BL-8040) and G-CSF Versus Placebo and G-CSF to Mobilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: The Genesis Trial

Low Utility of the H-Score and HLH-2004 Criteria to Identify Patients with Secondary Hemophagocytic Lymphohistiocytosis after CAR-T Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

The Impact of Bridging Therapy Prior to CAR-T Cell Therapy on Clinical Outcomes of Patients with Relapsed Refractory Large B-Cell Lymphoma

Long-Term Outcomes of Busulfan, Fludarabine and 400 Cgy Total Body Irradiation Versus Busulfan and Fludarabine Reduced-Intensity Conditioning Regimens for Allogeneic Stem Cell Transplantation in Hematologic Diseases: A Large Single Center Experience

A Single-Arm, Open-Label Phase 1 Study of Itacitinib (ITA) with Calcineurin Inhibitor (CNI)-Based Interventions for Prophylaxis of Graft-Versus-Host Disease (GVHD; GRAVITAS-119)

Bridging the Gap in Access to Transplant for Underserved Minority Patients Using Mismatched Unrelated Donors and Post-Transplant Cyclophosphamide: A National Marrow Donor Program/be the Match (NMDP/BTM) Initiative

Increased Cortical Glycolysis Following CD19 CART Therapy: A Radiographic Surrogate for an Altered Blood-Brain Barrier

Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CAR-T) for Large B-Cell Lymphoma: Predictive Biomarkers and Clinical Outcomes

Sublingual Microcirculatory Imaging As a Novel Tool to Monitor for Cytokine Release Syndrome after Chimeric Antigen Receptor T-Cell Therapy

Similar Survival for African American and Caucasian Multiple Myeloma Patients Receiving Auto-SCT

Plasma Cell Leukemia (PCL): Clinical Characteristics, Outcomes, and the Impact of Circulating Plasma Cells (CPC) Percentage — A Single Center Experience

Immunohematology and Transfusion Support of a Patient with Acute Myeloid Leukemia and an Anti-Vel

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only